A landmark study examining septic shock treatment strategies has revealed striking similarity in patient outcomes across treatment approaches. The CENSER trial, published in The New England Journal of Medicine, documented a 28% mortality rate at 90 days in both the early vasopressor group (27.9%) and the fluid resuscitation group (28.1%), based on data from 1,563 enrolled patients.
Organism dysfunction rates were similarly comparable, with the vasopressor-treated cohort showing 22.8% organ dysfunction compared to 23.9% in the fluid resuscitation group. These findings establish non-inferiority of the vasopressor approach and challenge the conventional wisdom that aggressive early fluid administration represents the optimal initial management strategy for septic shock.
The statistical equivalence across mortality and morbidity endpoints suggests that treatment selection may depend on additional clinical factors beyond survival outcomes, including fluid balance considerations and individual patient physiology. This data-driven evidence provides clinicians with a more nuanced understanding of septic shock management options.
Read the full article on GMJ Newsroom.
Was this article helpful?
